The BSI Tumour Immunology Group are excited to celebrate the relaunch of this Affinity Group with an inaugural high quality one-day meeting on Thursday 19 March 2020 at Austin Court Birmingham.
Immune checkpoint blockade has been making headlines for several years, transforming therapy for a range of previously untreatable advanced cancers. However, although some factors linked with improved responses are known, our understanding of the science underlying this approach is emphatically incomplete, and many patients do not respond to therapy, or experience serious side effects. The BSI Tumour Immunology Group have worked hard to put together a strong programme, focussing on exploring the fascinating and diverse immune axes that link with the checkpoint blockade concept.
In addition to providing a brief clinical perspective on current checkpoint blockade therapy, the range of speakers will explore the fundamental receptor-ligand systems involved in checkpoint blockade, key cellular subsets and regulatory axes, how the tumour and its microenvironment influence checkpoint blockade, followed by novel therapy developments in the checkpoint blockade area, including combination approaches and neoantigen reactive T cell therapy. The day will end with a networking session to bring together attendees from all stages of the therapeutic pathway, from basic scientists to translational clinicians and industry partners.
09:30–10:00 Welcome refreshments
10:00–10:15 Introduction Gary Middleton (University of Birmingham)
First session – Molecular mechanisms of checkpoint blockade
10:15–10:45 Simon Davis (University of Oxford)
10:45–11:15 Jannie Borst (Leiden University)
11:15–11:45 Sergio Quezada (University College London)
12:00 – 13:00 Lunch
Second session – Tumour genetics and microenvironment influencing checkpoint blockade
13:00–13:30 Ping-Chih Ho (University of Lausanne) - What intramural Tregs eat makes them strong but vulnerable
13:30–14:00 Shoba Amarnath (University of Newcastle)
14:00–14:30 David Withers (University of Birmingham) - Temporal in vivo labelling models to determine how immune cells change once within the tumour microenvironment
14:30–15:00 Nicholas McGranahan (University College London)
15:00 – 15:30 Break
Third session – Novel therapeutics and combinations
15:30–16:00 Jane Robertson (Achilles Therapeutics)
16:00–16:30 Juliet Gray (University of Southampton)
16:30–17:00 Gary Middleton (University of Birmingham)
17:00–18:15 Finish and refreshments with networking
Delegates are invited to submit abstracts for the opportunity to communicate their work. The abstract submission deadline is Thursday 20 February 2020. Please submit your abstract (max. 250 words) using this Google doc form.
|BSI Member - Full & Early Careers *||£30|
|BSI Member - Postgraduate (including PhD, Masters)||£20|
|BSI Member - Concessionary **||£20|
|Full & Early Careers *||£50|
|Postgraduate (including PhD, Masters)||£35|
|Undergraduate (membership is free)||£10|
* Early careers includes scientists employed as post-doctoral researchers, for the first 5 years post graduation.
** Concessionary includes Parental leave, Career Breaks, Retired, Emeritus Retired.
If you are interested in sponsoring this event, please email Jane Sessenwein.